SAN DIEGO--(BUSINESS WIRE)--Cardium Therapeutics, Inc. (OTCBB:CDTP) and its subsidiary Tissue Repair Company (TRC) today announced that Excellarate™, a DNA-based collagen gel, will advance to a Phase 2b clinical trial as a potential topical treatment for non-healing diabetic foot ulcers.
